Bristol-Myers Squibb (NYSE:BMY – Get Free Report)’s stock price traded down 0.1% on Thursday after Barclays lowered their price target on the stock from $43.00 to $41.00. Barclays currently has an equal weight rating on the stock. Bristol-Myers Squibb traded as low as $41.01 and last traded at $41.06. 2,982,313 shares changed hands during mid-day trading, a decline of 81% from the average session volume of 15,571,074 shares. The stock had previously closed at $41.12.
Other equities analysts also recently issued research reports about the stock. StockNews.com downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 27th. Wells Fargo & Company raised their price objective on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research note on Thursday, April 18th. BMO Capital Markets decreased their target price on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research report on Friday, April 26th. Finally, William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $59.50.
Institutional Trading of Bristol-Myers Squibb
Hedge funds and other institutional investors have recently modified their holdings of the business. ESL Trust Services LLC acquired a new stake in shares of Bristol-Myers Squibb during the 1st quarter worth about $27,000. Northwest Financial Advisors acquired a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth about $27,000. Accordant Advisory Group Inc acquired a new stake in shares of Bristol-Myers Squibb during the 1st quarter worth about $31,000. Pacific Capital Wealth Advisors Inc. acquired a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth about $34,000. Finally, VisionPoint Advisory Group LLC increased its position in shares of Bristol-Myers Squibb by 300.5% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 737 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 553 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.
Bristol-Myers Squibb Stock Down 0.9 %
The stock has a market capitalization of $82.59 billion, a price-to-earnings ratio of -13.25, a P/E/G ratio of 13.68 and a beta of 0.44. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11. The business has a 50-day moving average of $42.05 and a 200-day moving average of $47.52.
Bristol-Myers Squibb (NYSE:BMY – Get Free Report) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.53) by $0.13. The business had revenue of $11.87 billion during the quarter, compared to analysts’ expectations of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The business’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter last year, the business posted $2.05 EPS. On average, sell-side analysts expect that Bristol-Myers Squibb will post 0.58 EPS for the current year.
Bristol-Myers Squibb Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Thursday, August 1st. Investors of record on Friday, July 5th will be paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 5.89%. The ex-dividend date is Friday, July 5th. Bristol-Myers Squibb’s payout ratio is -77.42%.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.